Research and videos
Obicetrapib (CETP inhibitor): the research and Kevin's videos
Does obicetrapib lower Alzheimer's risk in APOE4 carriers, and when will it be available?
No Phoenix member data yet
This page has no results from Phoenix members yet. It shows what published research says, and what Kevin and the experts say in his videos.
See what Phoenix members have measuredDoes obicetrapib lower Alzheimer's risk in APOE4 carriers, and when will it be available?
Obicetrapib lowers LDL, ApoB and Lp(a), and in one trial substudy it may have slowed Alzheimer's blood markers, most of all in the small APOE4/4 group. That is a biomarker signal from one program, not proof that it prevents memory loss or heart attacks; those trials are still running. Ask your doctor about its approval status and any trial you could join.
What the research says
Grade CAPOE4-specific evidence: yes
Obicetrapib lowers LDL, ApoB and Lp(a) (high certainty) and may slow Alzheimer's blood markers in APOE4 carriers (low certainty, one substudy); it is not yet shown to prevent dementia or heart attacks.
Key studies
Nicholls 2025, N Engl J Med (BROADWAY)Grade A
Phase 3 trial in high-risk patients already on maximum lipid therapy: obicetrapib cut LDL by about a third over a year, with side effects similar to placebo.
Read on PubMed (opens in a new tab)Araujo 2025, Am J Prev CardiolGrade A
7 trials, 3,381 people: LDL down about 37%, Lp(a) about 37%, ApoB about 25%; new-onset diabetes 12% lower; no excess side effects.
Read on PubMed (opens in a new tab)Davidson 2026, J Prev Alzheimers Dis (BROADWAY substudy)Grade C
1,535 heart patients: obicetrapib slowed the rise in blood p-tau217 over 12 months; in the small APOE4/4 group p-tau217 fell 7.8% versus a 12.7% rise on placebo.
Read on PubMed (opens in a new tab)
3 more key studies
Schmidt 2024, Alzheimers Res Ther
Genetic (Mendelian randomization) study: naturally lower CETP went with less heart disease and lower Lewy body dementia risk.
Read on PubMed (opens in a new tab)Nicholls 2025, J Am Coll CardiolGrade C
Pooled, exploratory analysis of two trials: fewer coronary events on obicetrapib, appearing after 6 months; outcome trial still needed.
Read on PubMed (opens in a new tab)Barter 2007, N Engl J Med (ILLUMINATE)
An earlier CETP drug, torcetrapib, raised blood pressure and deaths; videos attribute this to the molecule, not the target.
Read on PubMed (opens in a new tab)
What Kevin and experts say
7 passages for, 3 with a caution, 1 also discussed
Now showing: Dr. Kevin Tran · 0:15
Open on YouTube (opens in a new tab)For7 passages
A cholesterol pill lowered an Alzheimer's blood marker in 4/4 carriers.
“ptau217, the cleanest blood biomarker we have for Alzheimer's pathology, dropped 7.81% on this drug and it went up 12.67% on placebo.”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
Obicetrapib looked as safe as placebo in trials.
“So, no blood pressure signal, lower discontinuation than placebo. This is a very very clean molecule.”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
More APOE4 copies, bigger obicetrapib effect.
“The effect scales with genetic risk.”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
Kevin would take obicetrapib on current evidence.
“for me, that number is big enough to definitely take the drug.”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
Obicetrapib reversed p-tau217's rise in 4/4 carriers.
“The E4 E4 carriers actually showed a massive difference of 20% and actually decrease of [p-tau] 217 in the [obicetrapib] group versus an increase over time in the placebo group.”
Dr. Philip Scheltens, Alzheimer Center Amsterdam, obicetrapib trial (AAIC 2025 clip)
An oral drug cut Lp(a) by nearly half in a trial.
Dr. Kevin Tran
Watch the Short on YouTube (opens in a new tab)
Genetics hinted CETP drugs may help carriers most against Lewy body dementia.
Dr. Kevin Tran
Watch the Short on YouTube (opens in a new tab)
With a caution3 passages
Confirming data come from the same program, not a new trial.
“it's still the same clinical program, not a different trial”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
Strongest signal yet, but not proven to prevent dementia.
“It's not yet proof of dementia prevention.”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
No safety data beyond one year and no proven survival benefit yet.
“We do not have long-term safety data beyond the trial duration, which is 1 year. We do not have confirmed cardiovascular mortality benefit”
Dr. Kevin Tran, Founder of The Phoenix Community, Doctor of Pharmacy, APOE4/4 carrier
Also discussed1 passage
The old CETP drug failed from side effects, not its target.
Dr. Kevin Tran
Watch the Short on YouTube (opens in a new tab)
Last reviewed
The Beat the Odds Study
The 43-page study: what members tried, how their bloodwork and wearable results changed, and what else changed alongside them.
Turn evidence into your next test
I built this so nobody has to be the first to try something.
476 members have already tried, measured and logged. Join Phoenix and your next blood draw joins the same Navigator you are reading.
Full research index
Find a goal, marker, intervention or question
Choose an outcome, like LDL cholesterol or sleep, or an intervention, like training: both paths open the same measured records.